Glass House Brands (GLAS) Cash & Equivalents (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Cash & Equivalents of $27.9 million for Q1 2026, down 25.76% year-over-year from $37.6 million in Q1 2025, and up 40.69% quarter-over-quarter from $19.8 million in Q4 2025.
Glass House Brands (GLAS) Cash & Equivalents (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Cash & Equivalents for 7 consecutive years, with $27.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents fell 25.76% year-over-year to $27.9 million; the TTM figure through Mar 2026 stood at $27.9 million (down 25.76% YoY), while the FY2025 annual figure was $19.8 million, down 41.49% from the prior year.
- Cash & Equivalents grew to $27.9 million in Q1 2026 per GLAS's latest filing, from $19.8 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $44.2 million in Q2 2025 and bottomed at $11.1 million in Q4 2022.
- Historically, Cash & Equivalents has averaged $26.8 million across 5 years, with a median of $25.9 million in 2024.
- Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 93.34% — and 2023, when it jumped 164.94%.
- Glass House Brands' Cash & Equivalents stood at $11.1 million in 2022, then surged by 164.94% to $29.5 million in 2023, then climbed by 14.9% to $33.9 million in 2024, then slumped by 41.49% to $19.8 million in 2025, then jumped by 40.69% to $27.9 million in 2026.
- Business Quant data shows GLAS's Cash & Equivalents at $27.9 million in Q1 2026, $19.8 million in Q4 2025, and $29.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Glass House Brands | 831.09 Mn | 812.54 Mn | 15.77 Mn | 18.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.93 Mn |
| Dec 31, 2025 | 19.85 Mn |
| Sep 30, 2025 | 29.77 Mn |
| Jun 30, 2025 | 44.20 Mn |
| Mar 31, 2025 | 37.62 Mn |
| Dec 31, 2024 | 33.92 Mn |
| Sep 30, 2024 | 35.06 Mn |
| Jun 30, 2024 | 25.88 Mn |
| Mar 31, 2024 | 24.41 Mn |
| Dec 31, 2023 | 29.52 Mn |
| Sep 30, 2023 | 37.89 Mn |
| Jun 30, 2023 | 22.69 Mn |
| Mar 31, 2023 | 16.37 Mn |
| Dec 31, 2022 | 11.14 Mn |
| Sep 30, 2022 | 17.54 Mn |
| Jun 30, 2022 | 17.45 Mn |
| Mar 31, 2022 | 24.83 Mn |
| Dec 31, 2021 | 51.07 Mn |
| Sep 30, 2021 | 28.86 Mn |
| Jun 30, 2021 | 134.28 Mn |